HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $457
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Vertex Pharmaceuticals (VRTX) and raises the price target from $397 to $457.
February 06, 2024 | 11:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vertex Pharmaceuticals' price target was raised from $397 to $457 by HC Wainwright & Co., maintaining a Buy rating.
The increase in the price target for Vertex Pharmaceuticals by a reputable analyst firm, HC Wainwright & Co., suggests a strong bullish outlook on the stock. This is likely to instill confidence in investors, potentially driving up the stock price in the short term. The maintenance of a Buy rating further reinforces the positive sentiment towards VRTX.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100